Skip to content
Sign in
StableHealthPolicyScienceReported 2026-11-09 20:00

Edesa Biotech and KYORIN Pharmaceutical Enter into Exclusive Collaboration for Paridiprubart in Japan

Edesa Biotech and KYORIN Pharmaceutical have entered into an exclusive collaboration for the development and commercialization of paridiprubart in Japan, with Kyorin obtaining exclusive rights and Edesa receiving upfront and milestone payments, plus royalties.

In depthRead the in-depth story

Why it matters. Edesa Biotech gains a strategic partner in Japan, a major pharmaceutical market, for its potential first-in-class antibody for ARDS, while Kyorin secures an innovative therapeutic candidate.

01

Evidence

  • GGDELT Global Knowledge GraphMedia2026-11-09 19:30
    View source
  • GGDELT Global Knowledge GraphMedia2026-11-09 20:00
    View source